https://www.live-feeds.com/feed/merck-ceo-tells-cnbc-he-expects-breakthrough-cancer-vaccine-will-become-faster-to-makeContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/merck-ceo-tells-cnbc-he-expects-breakthrough-cancer-vaccine-will-become-faster-to-makehttps://www.live-feeds.com/feed/merck-ceo-tells-cnbc-he-expects-breakthrough-cancer-vaccine-will-become-faster-to-make#u131832Sun, 18 Oct 2026 12:45:48 +0000Merck CEO Rob Davis expects the manufacturing timeline for the company's personalized cancer vaccine, developed with partner Moderna, to shrink over time. Davis shared this outlook with CNBC on Wednesday following the official opening of Merck's new 120,000-square-foot research facility in the Greater Philadelphia area. Accelerated manufacturing could eventually enable broader patient access to the breakthrough therapy as the pipeline strategy advances and the story transitions from the laboratory to commercial-scale production.Why it mattersThe collaboration between Merck and Modern